Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Hecht, Markus; Gostian, Antoniu Oreste; Eckstein, Markus; Rutzner, Sandra; von der Grün, Jens; Illmer, Thomas; Hautmann, Matthias G; Klautke, Gunther; Laban, Simon; Brunner, Thomas; Hinke, Axel; Becker, Ina; Frey, Benjamin; Semrau, Sabine; Geppert, Carol I; Hartmann, Arndt; Balermpas, Panagiotis; Budach, Wilfried; Gaipl, Udo S; Iro, Heinrich

doi:10.1136/jitc-2020-001378

Citations

Citation copied

Hecht, M., Gostian, A. O., Eckstein, M., Rutzner, S., von der Grün, J., Illmer, T., Hautmann, M. G., Klautke, G., Laban, S., Brunner, T., Hinke, A., Becker, I., Frey, B., Semrau, S., Geppert, C. I., Hartmann, A., Balermpas, P., Budach, W., Gaipl, U. S., … Fietkau, R. (2020). Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. Journal for ImmunoTherapy of Cancer, 8, e001378. https://doi.org/10.1136/jitc-2020-001378

Abstract

Background: To determine safety and efficacy of single cycle induction treatment with cisplatin/docetaxel and durvalumab/tremelimumab in stage III-IVB head and neck cancer.

Methods: Patients received a single cycle of cisplatin 30 mg/m² on days 1–3 and docetaxel 75 mg/m² on day 1 combined with durvalumab 1500 mg fix dose on day 5 and tremelimumab 75 mg fix dose on day 5. Patients with pathologic complete response (pCR) in the rebiopsy after induction treatment or at least 20% increase of intratumoral CD8+ cell density in the rebiopsy